Literature DB >> 27517842

Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease.

Amanda M Brandow1, Mark Nimmer2, Timothy Simmons3, T Charles Casper3, Lawrence J Cook3, Corrie E Chumpitazi4, J Paul Scott1, Julie A Panepinto1, David C Brousseau2.   

Abstract

The impact of emergency department (ED) treatment on outcomes of sickle cell disease (SCD) acute pain hospitalizations is not well described. We investigated whether length of stay (LOS) and change in health-related quality of life (HRQL) are affected by initial opioid dose and time to administration. We conducted secondary analyses of data from the randomized-controlled Magnesium for children in Crisis (MAGiC) trial. The primary outcome was LOS. Secondary outcome was change in HRQL, assessed using PedsQL SCD Pain and Hurt and Pain Impact Domains measured in ED and at discharge. Independent variables were (1) time to first IV opioid, (2) total initial opioid dose (mg/kg/hr of morphine equivalents administered between ED and first study drug), and (3) Time to first oral opioid. Spearman correlations determined the associations with LOS. Using two-sample t-tests, we compared mean change in HRQL scores between IV opioid initiated within 60 and >60 min, opioid doses in the highest and lowest tertiles, and oral opioid initiated within 24 and >24 hr. Two hundred and four patients participated at 8 sites. Mean (SD) age was 13.6 (4.7) years. Earlier initiation of oral opioids was strongly correlated with shorter LOS (r = 0.61, P < 0.01). Higher initial opioid dose was weakly correlated with longer LOS (r = 0.34, P < 0.01). Higher initial opioid doses (6 vs -2.2; P = 0.01) and oral opioids initiated within 24 hr (5.7 vs -1.7, P = 0.04) were associated with larger mean change in HRQL at discharge. Prospective trials evaluating the impact of ED care on outcomes of pain hospitalizations could improve SCD pain treatment. Am. J. Hematol. 91:1175-1180, 2016.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27517842     DOI: 10.1002/ajh.24534

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  15 in total

1.  American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain.

Authors:  Amanda M Brandow; C Patrick Carroll; Susan Creary; Ronisha Edwards-Elliott; Jeffrey Glassberg; Robert W Hurley; Abdullah Kutlar; Mohamed Seisa; Jennifer Stinson; John J Strouse; Fouza Yusuf; William Zempsky; Eddy Lang
Journal:  Blood Adv       Date:  2020-06-23

2.  HABIT, a Randomized Feasibility Trial to Increase Hydroxyurea Adherence, Suggests Improved Health-Related Quality of Life in Youths with Sickle Cell Disease.

Authors:  Arlene Smaldone; Sally Findley; Deepa Manwani; Haomiao Jia; Nancy S Green
Journal:  J Pediatr       Date:  2018-03-20       Impact factor: 4.406

Review 3.  Improving Emergency Department-Based Care of Sickle Cell Pain.

Authors:  Jeffrey A Glassberg
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 4.  Pain-measurement tools in sickle cell disease: where are we now?

Authors:  Deepika S Darbari; Amanda M Brandow
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 5.  Optimizing the care model for an uncomplicated acute pain episode in sickle cell disease.

Authors:  Paul Telfer; Banu Kaya
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

6.  Impact of early analgesia on hospitalization outcomes for sickle cell pain crisis.

Authors:  Jason Payne; Inmaculada Aban; Lee M Hilliard; Jennifer Madison; Christina Bemrich-Stolz; Thomas H Howard; Amanda Brandow; Emily Waite; Jeffrey D Lebensburger
Journal:  Pediatr Blood Cancer       Date:  2018-08-27       Impact factor: 3.167

7.  End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain.

Authors:  Ann T Farrell; Julie Panepinto; C Patrick Carroll; Deepika S Darbari; Ankit A Desai; Allison A King; Robert J Adams; Tabitha D Barber; Amanda M Brandow; Michael R DeBaun; Manus J Donahue; Kalpna Gupta; Jane S Hankins; Michelle Kameka; Fenella J Kirkham; Harvey Luksenburg; Shirley Miller; Patricia Ann Oneal; David C Rees; Rosanna Setse; Vivien A Sheehan; John Strouse; Cheryl L Stucky; Ellen M Werner; John C Wood; William T Zempsky
Journal:  Blood Adv       Date:  2019-12-10

8.  The association between timely opioid administration and hospitalization in children with sickle cell disease presenting to the emergency department in acute pain.

Authors:  Cagla S Muslu; Matthew Kopetsky; Mark Nimmer; Alexis Visotcky; Raphael Fraser; David C Brousseau
Journal:  Pediatr Blood Cancer       Date:  2020-07-02       Impact factor: 3.167

Review 9.  Key Components of Pain Management for Children and Adults with Sickle Cell Disease.

Authors:  Amanda M Brandow; Michael R DeBaun
Journal:  Hematol Oncol Clin North Am       Date:  2018-06       Impact factor: 3.722

10.  Magnesium for treating sickle cell disease.

Authors:  Nan Nitra Than; Htoo Htoo Kyaw Soe; Senthil K Palaniappan; Adinegara Bl Abas; Lucia De Franceschi
Journal:  Cochrane Database Syst Rev       Date:  2019-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.